ZS Per­spec­tive: 3 Pre­dic­tions on the Fu­ture of Cell & Gene Ther­a­pies

4 years ago

The Price of Re­lief: Ex­plor­ing So­lu­tions to the Ris­ing Costs of On­col­o­gy Drugs

4 years ago

Map­ping the Fu­ture of De­cen­tral­ized Clin­i­cal Tri­als

4 years ago

The $8m Ques­tion - Why and When Pa­tients Leave the Re­cruit­ment Jour­ney

4 years ago

Hema­tol­ogy: How Far We’ve Come, Where We Go Next

4 years ago

mHealth in­no­va­tion: Iden­ti­fy­ing the best pa­tient-cen­tered tech­nol­o­gy for clin­i­cal tri­als

4 years ago

Op­ti­miz­ing Oral Drug De­liv­ery us­ing Zy­dis® Oral­ly Dis­in­te­grat­ing Tablet Tech­nol­o­gy to Ad­dress Pa­tient Chal­lenges

4 years ago

In­cor­po­rat­ing Ex­ter­nal Da­ta in­to Clin­i­cal Tri­als: Com­par­ing Dig­i­tal Twins to Ex­ter­nal Con­trol Arms

4 years ago

At the In­flec­tion Point for the Next Gen­er­a­tion of Can­cer Im­munother­a­py

4 years ago

No IND Re­quired for Cell and Gene Ther­a­py Stud­ies with Aus­tralia’s Ac­cred­it­ed CRO Avance Clin­i­cal

4 years ago

Clin­i­cal tri­al adap­ta­tions made dur­ing the pan­dem­ic re­veal an in­dus­try em­brac­ing change

4 years ago

Start­ing Strong with As­sured Sup­ply of Qual­i­ty Ma­te­ri­als for Im­mune Cell Ther­a­pies

4 years ago

In­no­va­tion by Dis­rup­tion: Break­ing Si­los Be­tween R&D and Com­mer­cial Teams to Ad­vance New Treat­ments for Pa­tients

4 years ago

Risk Mit­i­ga­tion in Di­rect-to-Pa­tient Clin­i­cal Tri­als

4 years ago

Biotech and Big Phar­ma: A blue­print for a suc­cess­ful part­ner­ship

4 years ago

Biotech Half­time Re­port: Af­ter a bumpy year, is biotech ready to re­bound?

4 years ago

eCOA Clin­i­cal Tri­als: A Sim­ple, Cost-Ef­fec­tive Ap­proach to Study Build

4 years ago

Why it Works: Man­u­fac­tur­ing a Vac­cine in a Mul­ti-Prod­uct Fa­cil­i­ty.

4 years ago

Health­care Dis­par­i­ties and Sick­le Cell Dis­ease

4 years ago

What Will it Take to Re­al­ize the Promise and Po­ten­tial of Im­mune Cell Ther­a­pies?

4 years ago

Ge­net­ic Med­i­cine Leads a Surge of In­no­va­tion in Biotech

4 years ago

Berke­ley Lights’ unique func­tion-first ap­proach pro­vides ad­vance­ments in time­line, qual­i­ty, and rev­enues

4 years ago

Is Your Tech­nol­o­gy Keep­ing Pace with Your Sci­ence?

4 years ago

Adap­tive De­sign Meth­ods Of­fer Rapid, Seam­less Tran­si­tion Be­tween Study Phas­es in Rare Can­cer Tri­als

4 years ago
First page Previous page 3456789 Next page Last page
A service from the Financial Times